Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: blood loss (228), haemorrhage (88), flow (235)

Craniotomy for brain tumour removal - patient information

Description: A craniotomy is an operation where a disc of bone is removed from the skull using special tools to allow access
Url: /Media/UHS-website-2019/Patientinformation/Brain-and-spine/Craniotomy-for-brain-tumour-removal-1192-PIL.pdf

Cisplatin, Vinorelbine and radiotherapy

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN - VINORELBINE (RADIOTHERAPY) Regimen NSCLC – Cisplatin - Vinorelbine (Radiotherapy) Indication First line therapy of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CisplatinVinorelbineandradiotherapyver12.pdf

Cisplatin and Vinorelbine (intravenous-adjuvant)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-VINORELBINE (Intravenous - Adjuvant) Regimen NSCLC – Cisplatin-Vinorelbine (Intravenous-Adjuvant) Indication Adjuvant therapy
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CisplatinandVinorelbineintravenous-adjuvantver12.pdf

Cisplatin and Vinorelbine (intravenous)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-VINORELBINE (Intravenous) Regimen NSCLC – Cisplatin-Vinorelbine IV Indication First line therapy of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CisplatinandVinorelbineintravenousver12.pdf

Cisplatin and Gemcitabine

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-GEMCITABINE Regimen NSCLC – Cisplatin-Gemcitabine Indication Non-small cell lung cancer (in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CisplatinandGemcitabinever12.pdf

Paclitaxel (7 day)

Description: Chemotherapy Protocol BLADDER CANCER PACLITAXEL (7 day) Regimen • Bladder Cancer – Paclitaxel (7 day) Indication • Treatment of locally advanced or metastatic bladder
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Paclitaxel-7-day.pdf

Mitoxantrone-Prednisolone ver1.2

Description: Chemotherapy Protocol PROSTATE MITOXANTRONE-PREDNISOLONE Regimen  Prostate-Mitoxantrone-Prednisolone Indication  Castrate resistant prostate cancer  Performance status 0, 1, 2  Palliative Toxicity
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Mitoxantrone-Prednisolone-ver1.2.pdf

Pemetrexed (maintenance)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) PEMETREXED (Maintenance) Regimen NSCLC – Pemetrexed (Maintenance) Indication Pemetrexed is recommended as an option
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pemetrexedmaintenancever11.pdf

Vinflunine

Description: Chemotherapy Protocol BLADDER Regimen VINFLUNINE • Bladder – Vinflunine Indication • Bladder cancer that has failed to respond or progressed with in twelve months
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Vinflunine.pdf

Ibrutinib (MCL) (560mg)

Description: Chemotherapy Protocol Mantle Cell Lymphoma Regimen Ibrutinib • MCL – Ibrutinib (560mg) Indication • Mantle Cell Ly
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Ibrutinib-MCL-560mg.pdf

311 to 320 of 705

Previous … 30 31 32 33 34 … Next